TLR4

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Retrieved on: 
Wednesday, March 13, 2024
Health, Infectious Diseases, Surgery, General Health, Clinical Trials, Pharmaceutical, Biotechnology, CRRT, Conference, Rat, Disease, AKI, TLR4, Acute kidney injury, Immunity, Toll-like receptor 4, Poster, Animal, Kidney

Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI.

Key Points: 
  • Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI.
  • A copy of the presentation and poster presented at the AKI and CRRT 2024 Conference can be found on Revelation’s website .
  • In addition to clinical observation, rats were evaluated for markers of kidney function at 24 and/or 72 hours post-surgery, and markers of kidney damage at 72 hours post-surgery.
  • Reduced overall damage (necrosis) of the cortical (p

TRS01 for Autoimmune Uveitis in Seven Major Markets: Size, Forecasts, and Emerging Insights, 2019-2023 and 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2024
Health, Pharmaceutical, Toll-like receptor 4, Uveitis, SWOT, EU4, TRS, Autoimmunity, TLR4, Research, Immune system, Pharmaceutical industry

This report provides comprehensive insights about TRS01 for autoimmune uveitis in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about TRS01 for autoimmune uveitis in the seven major markets.
  • Further, it also consists of future market assessments inclusive of the TRS01 market forecast analysis for autoimmune uveitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in autoimmune uveitis.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TRS01 in autoimmune uveitis.
  • The report also features the SWOT analysis with analyst views for TRS01 in autoimmune uveitis.

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Retrieved on: 
Monday, March 4, 2024
Health, Infectious Diseases, Surgery, Clinical Trials, Research, Science, Biotechnology, Diabetes, Incidence, Toll-like receptor 4, Fungal infection, Gemini, Infection, Safety, Biomarker, Ischemia, Acute kidney injury, Patient, AKI, Disease, Immunity, Trial of the century, TLR4, Genetically modified bacteria, Pharmaceutical industry

The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of age.

Key Points: 
  • The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of age.
  • Data from this Phase 1 clinical study will support future development across multiple indications.
  • Preclinical studies using models of AKI have demonstrated pretreatment with Gemini can reduce the severity and duration of AKI.
  • The start of this study is an important step toward bringing a potential new therapy for these unmet needs.”

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Retrieved on: 
Tuesday, January 30, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Senior, CRRT, AKI, Acute kidney injury, Toll-like receptor 4, TLR4, Conference

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024).

Key Points: 
  • Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024).
  • Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI and hospital acquired infection.
  • Robin Marsden, Senior Vice President of Biology, Revelation Biosciences
    “We are delighted to have the opportunity to present our exciting preclinical data for the prevention of acute kidney injury (AKI),” said James Rolke, Chief Executive Officer of Revelation.
  • “We are grateful to the conference organizers for creating a forum for industry, academia, and key opinion leaders to share data and ideas in this critical area of medicine.”

HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq

Retrieved on: 
Tuesday, January 23, 2024
Patient, Sarcoma, Biotechnology, Cancer, Ecosystem, GMP, Orsay, Oncology, TLR4, Investment, Pharmaceutical industry

HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq

Key Points: 
  • HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq
    1st institutional round for HEPHAISTOS-Pharma, getting on track to bring its lead product ONCO-Boost to the clinic.
  • HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer, today announced that it has raised a €2 million seed round to finance GMP transfer and advance its lead candidate towards the clinic.
  • The round was co-led by xista science ventures and the Foundation Fournier-Majoie, with the participation of Noshaq.
  • « The Foundation is very pleased to be part of HEPHAISTOS-Pharma thanks to this financing round.

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Retrieved on: 
Thursday, August 10, 2023
Part 1, Blood pressure, CSO, Chills, Fever, Aes, Toxicity, LPS, Temperature, TLR4, Vomiting, Plasma, Patient, Nausea, Chemokine, Heart rate, Recommended exposure limit, Therapy, Safety, Fatigue, Protocol, Pharmaceutical industry, Vaccine

Four patients were enrolled and evaluable in this cohort.

Key Points: 
  • Four patients were enrolled and evaluable in this cohort.
  • Overall, patients experienced symptoms or adverse events (AEs) that were short-lived and consistent with the mechanism of action of Decoy20.
  • “The safety profile exhibited among the first cohort of patients in our Phase 1 dose ranging study was consistent with the Decoy20 mechanism of action.
  • We expect the enrollment of the next cohort will bring us closer to determination of the recommended phase 2 dose for the multi-dosing part of the trial.

Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004

Retrieved on: 
Wednesday, August 2, 2023
University, Rhinitis, Clinical trial, Therapeutic Goods Administration, Allergic rhinitis, Pharmacokinetics, Quality of life, University of South Florida, SAD, CMO, TLR4, MD, Division, Drug discovery, MAD, FIH, TGA, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Allergic inflammation, AR, Food, Safety, Pharmaceutical industry

MISSOULA, Mont., Aug. 2, 2023 /PRNewswire/ -- Inimmune Corporation ("Inimmune"), a clinical-stage company focused on the development of innovative immunotherapeutics, today announced that the first subject has been dosed in Inimmune's phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune's TLR4 agonist product candidate under development as a potential treatment of allergic rhinitis.

Key Points: 
  • The phase 1/1b trial is a randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INI-2004 in healthy volunteers and participants with allergic rhinitis (AR).
  • "Australia is the ideal location for us to conduct a cost-effective, high-quality phase 1 study," said Jon Ruckle, MD, CMO.
  • "We already have in place an Australian subsidiary, an experienced phase 1 clinical site, and a relationship with a well-respected local contract research organization."
  • "INI-2004 leverages our groundbreaking science as it was designed to be allergen-agnostic and can potentially be an effective treatment for multiple allergic diseases."

Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies

Retrieved on: 
Thursday, April 20, 2023
OTC Markets Group, Infection, Food and Drug Administration Amendments Act of 2007, Cancer, TLR4, Driver License Agreement, Patient, Statera BioPharma, License, Autoimmune disease, Therapy, Pharmaceutical industry

3 to the License Agreement, Biostax will pay royalties to Statera and obtain worldwide exclusive rights to numerous patents surrounding Low-dose Naltrexone and Met-enkephalin (MENK), for all indications except Crohn’s Disease, which Statera will continue to develop and commercialize.

Key Points: 
  • 3 to the License Agreement, Biostax will pay royalties to Statera and obtain worldwide exclusive rights to numerous patents surrounding Low-dose Naltrexone and Met-enkephalin (MENK), for all indications except Crohn’s Disease, which Statera will continue to develop and commercialize.
  • Detailed terms about the settlement and the amended license agreement may be found at www.biostaxcorp.com and www.staterabiopharma.com .
  • Kelly Wilson, Chief Executive Officer of Biostax Corp. said, “This settlement agreement is an important step for Biostax, as it supports solidifying and expanding our position within the low-dose naltrexone and TLR4 space.
  • We believe that this settlement is beneficial to our company, shareholders, and potential patients.

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Retrieved on: 
Wednesday, April 19, 2023
NOD2, AACR, Therapy, Neoplasm, Cancer, American Association for Cancer Research, TLR9, NSAID, Breast, Research, LDC, TLR4, TLR2, Patient, NLR, TLR8, Poster, Metastasis, Pharmaceutical industry, Vaccine

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform.

Key Points: 
  • NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform.
  • The poster, titled, “ A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy ,” authored by Michael J. Newman, Ph.D., the Company’s Founder and Chief Scientific Officer, was presented Tuesday, April 18, 2023.
  • Regressions were also seen with Decoy10 in combination with a non-steroidal anti-inflammatory drug (NSAID), an anti-PD-1 checkpoint inhibitor, low-dose chemotherapy (LDC), and LDC plus a targeted antibody.
  • Importantly, our results demonstrate the potential for activity in multiple solid tumor indications with high unmet need and the flexibility to be combined with a wide variety of synergy partners.

Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction

Retrieved on: 
Wednesday, March 1, 2023
Chronic liver disease, Therapy, Form, Autoimmune hepatitis, OTC Markets Group, Disease, Acquisition, Patient, Security (finance), Hope, CUSIP, Gompertz distribution, TLR4, NASH, Reward, DEF, Internal, Risk, Health care, Pharmaceutical industry

Coinciding with the name change, the company has also unveiled their new website https://biostaxcorp.com that details their upcoming plans and new business strategies.

Key Points: 
  • Coinciding with the name change, the company has also unveiled their new website https://biostaxcorp.com that details their upcoming plans and new business strategies.
  • The company has already registered Biostax Corp as a “Fictitious Name,” with Florida allowing them to “do business as” (d/b/a) Biostax Corp.
  • The name change will take effect after the DEF 14-C is filed and once state and federal agencies approve and process the change.
  • Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition.